JP2022532994A5 - - Google Patents
Info
- Publication number
- JP2022532994A5 JP2022532994A5 JP2021563350A JP2021563350A JP2022532994A5 JP 2022532994 A5 JP2022532994 A5 JP 2022532994A5 JP 2021563350 A JP2021563350 A JP 2021563350A JP 2021563350 A JP2021563350 A JP 2021563350A JP 2022532994 A5 JP2022532994 A5 JP 2022532994A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- fusion protein
- cdr2
- cdr3
- cdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839376P | 2019-04-26 | 2019-04-26 | |
| US62/839,376 | 2019-04-26 | ||
| PCT/US2020/029967 WO2020219989A1 (en) | 2019-04-26 | 2020-04-24 | Compositions and methods for treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022532994A JP2022532994A (ja) | 2022-07-21 |
| JP2022532994A5 true JP2022532994A5 (https=) | 2023-05-02 |
Family
ID=72941772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563350A Pending JP2022532994A (ja) | 2019-04-26 | 2020-04-24 | がんの治療のための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220387487A1 (https=) |
| EP (1) | EP3958876A4 (https=) |
| JP (1) | JP2022532994A (https=) |
| KR (1) | KR20220003045A (https=) |
| CN (1) | CN114007626A (https=) |
| AU (1) | AU2020262956A1 (https=) |
| BR (1) | BR112021021299A2 (https=) |
| CA (1) | CA3137962A1 (https=) |
| IL (1) | IL287538A (https=) |
| MX (1) | MX2021013117A (https=) |
| WO (1) | WO2020219989A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3240805T3 (fi) * | 2014-12-15 | 2025-02-17 | Univ California | Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori |
| WO2024055023A2 (en) * | 2022-09-08 | 2024-03-14 | Virogin Biotech Canada Ltd | Adapter for universal tumor targeting |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2322547A1 (en) * | 2003-06-25 | 2011-05-18 | Crucell Holland B.V. | Myeloid cell-specific lectin |
| EP2563816B1 (en) * | 2010-04-27 | 2014-11-12 | National Research Council of Canada | Anti-icam-1 single domain antibody and uses thereof |
| US11655452B2 (en) * | 2015-06-25 | 2023-05-23 | Icell Gene Therapeutics Inc. | Chimeric antigen receptors (CARs), compositions and methods of use thereof |
| US10508143B1 (en) * | 2015-10-30 | 2019-12-17 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| HK1258375A1 (zh) * | 2015-11-24 | 2019-11-08 | Onk Therapeutics Limited | 人源化抗-cll-1抗体 |
| GB201607968D0 (en) * | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
| US20210139579A1 (en) * | 2017-07-20 | 2021-05-13 | Nbe-Therapeutics Ag | Multispecific antibody product that binds to different ror1 epitopes |
| US11891426B2 (en) * | 2017-12-15 | 2024-02-06 | Aleta Biotherapeutics Inc. | CD19 variants |
| EP3850013A4 (en) * | 2018-09-10 | 2022-10-05 | Nanjing Legend Biotech Co., Ltd. | SINGLE DOMAIN ANTIBODIES AGAINST CLL1 AND USES THEREOF |
-
2020
- 2020-04-24 WO PCT/US2020/029967 patent/WO2020219989A1/en not_active Ceased
- 2020-04-24 JP JP2021563350A patent/JP2022532994A/ja active Pending
- 2020-04-24 US US17/605,711 patent/US20220387487A1/en not_active Abandoned
- 2020-04-24 CA CA3137962A patent/CA3137962A1/en active Pending
- 2020-04-24 AU AU2020262956A patent/AU2020262956A1/en not_active Abandoned
- 2020-04-24 MX MX2021013117A patent/MX2021013117A/es unknown
- 2020-04-24 BR BR112021021299A patent/BR112021021299A2/pt not_active IP Right Cessation
- 2020-04-24 KR KR1020217038771A patent/KR20220003045A/ko not_active Ceased
- 2020-04-24 CN CN202080046175.XA patent/CN114007626A/zh active Pending
- 2020-04-24 EP EP20795219.3A patent/EP3958876A4/en not_active Withdrawn
-
2021
- 2021-10-24 IL IL287538A patent/IL287538A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI788327B (zh) | 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途 | |
| JP2020525032A5 (https=) | ||
| JP6676521B2 (ja) | 二重特異性分子、薬学的組成物及びそれらの使用 | |
| US12428493B2 (en) | Antibodies that bind PSMA and gamma-delta T cell receptors | |
| JP2021522162A5 (https=) | ||
| IL268901B1 (en) | Human immunoglobulin M constant regions adapted for modulation of complement-dependent cytolysis factor activity | |
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| RU2018143439A (ru) | Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf и pd1-связывающий фрагмент | |
| CN118852460A (zh) | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA) | |
| JP2017532952A5 (https=) | ||
| JP2017529067A (ja) | Ｃｄ３結合ドメイン | |
| JP2022545647A5 (https=) | ||
| TW202221021A (zh) | 改良之抗原結合受體 | |
| JP2018522888A5 (https=) | ||
| JP2022512891A5 (https=) | ||
| JP2022549172A5 (https=) | ||
| CN115461371A (zh) | 靶向ox40的抗体及其制备方法和应用 | |
| JP7558534B2 (ja) | Ｃｄ１３７アゴニスト性抗体とその使用 | |
| JP2021518132A5 (https=) | ||
| JP2022532994A5 (https=) | ||
| JP2023533533A5 (https=) | ||
| US20230340119A1 (en) | Composition of triax antibodies and method of making and using thereof | |
| CN115746144B (zh) | 抗tigit-pd1双特异性抗体及其应用 | |
| WO2024193669A1 (zh) | 抗tnfr2/抗pd-1或ctla-4双特异性抗体及其应用 | |
| JP2025516805A (ja) | 固形腫瘍を治療する方法 |